Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro

Jackelyn Murray, Robert J. Hogan, David E. Martin, Kathy Blahunka, Fred D. Sancilio, Rajiv Balyan, Mark Lovern, Richard Still, Ralph A. Tripp

Research output: Contribution to journalArticlepeer-review

22 Citations (Scopus)
18 Downloads (Pure)

Abstract

Effective vaccines are slowing the COVID-19 pandemic, but SARS-CoV-2 will likely remain an issue in the future making it important to have therapeutics to treat patients. There are few options for treating patients with COVID-19. We show probenecid potently blocks SARS-CoV-2 replication in mammalian cells and virus replication in a hamster model. Furthermore, we demonstrate that plasma concentrations up to 50-fold higher than the protein binding adjusted IC90 value are achievable for 24 h following a single oral dose. These data support the potential clinical utility of probenecid to control SARS-CoV-2 infection in humans.

Original languageEnglish
Article number18085
Pages (from-to)1-7
Number of pages7
JournalScientific Reports
Volume11
Issue number1
DOIs
Publication statusPublished - Dec 2021
Externally publishedYes

Fingerprint

Dive into the research topics of 'Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro'. Together they form a unique fingerprint.

Cite this